OSMOVIST 240 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Osmovist 240, and what generic alternatives are available?
Osmovist 240 is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in OSMOVIST 240 is iotrolan. There is one drug master file entry for this compound. Additional details are available on the iotrolan profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for OSMOVIST 240?
- What are the global sales for OSMOVIST 240?
- What is Average Wholesale Price for OSMOVIST 240?
Summary for OSMOVIST 240
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 26 |
| Patent Applications: | 1,302 |
| DailyMed Link: | OSMOVIST 240 at DailyMed |
US Patents and Regulatory Information for OSMOVIST 240
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | OSMOVIST 240 | iotrolan | INJECTABLE;INTRATHECAL | 019580-002 | Dec 7, 1989 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
